Witryna6 maj 2024 · First Quarter 2024 Financial Results. The Company’s cash, cash equivalents, and restricted cash totaled $129.9 million as of March 31, 2024, compared to $95.1 million as of December 31, 2024. The Company had 215.6 million shares of common stock outstanding as of March 31, 2024. Research and development … Witryna8 lis 2024 · Ocugen is building its own manufacturing suites to prepare for a NeoCart® clinical trial and as part of an overall research and development expansion. Third Quarter 2024 Financial Results. The Company’s cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2024, compared to $95.1 million as of …
Press Releases Ocugen, Inc.
Witryna1 kwi 2024 · Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and ... Witryna27 mar 2024 · Most relevant news about OCUGEN, INC. 07:42a: Ocugen : Q4 Earnings Snapshot: AQ rbm allround bord
OCUGEN AKTIEN News A2PSZH Nachrichten
Witryna8 lis 2024 · Ocugen is building its own manufacturing suites to prepare for a NeoCart® clinical trial and as part of an overall research and development expansion. Third … Witryna14 kwi 2024 · Ocugen will continue to monitor long-term safety and efficacy data from the treated patients, and advance development of OCU400 to bring a potential treatment option to RP and LCA patients. CanSinoBIO, Ocugen’s strategic partner, provided all CMC development and clinical supplies for the Phase 1/2 trial of OCU400. Witryna9 sty 2024 · MALVERN, Pa., Jan. 09, 2024 (GLOBE NEWSWIRE) -- , Inc. (Ocugen) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, … rbm apprenticeship